A narrative review of the socioeconomic burden associated with generalised pustular psoriasis

• Published in: Experimental dermatology 2023-08, Vol.32 (8), p.1219-1226
• Main Authors: Zimmermann, Thomas M., Hofmann, Patrick, Chiu, Gretchen R.
• Format: Article
• Language: English
• Subjects: Absenteeism; Comorbidity; Exanthema; Hospitalization; Humans; inflammation; inflammatory skin diseases; Intensive care; Patients; Psoriasis; Psoriasis - diagnosis; Psoriasis - epidemiology; Psoriasis - therapy; Quality of Life; Resource utilization; Sepsis; Skin diseases; Socioeconomic Factors
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.14841

Generalised pustular psoriasis (GPP) is a rare, chronic and life‐threatening inflammatory skin disease characterised by widespread eruption of sterile pustules. With the approval of a GPP flare treatment in several countries occurring only recently, the socioeconomic burden associated with GPP is not well established. To highlight current evidence for patient burden, healthcare resource utilization (HCRU) and costs associated with GPP. Patient burden results from serious complications including sepsis and cardiorespiratory failure causing hospitalization and death. HCRU is driven by high hospitalization rates and treatment costs. The mean duration of a GPP hospital stay ranges from 10 to 16 days. A quarter of patients require intensive care, and the mean intensive care stay is 18 days. In comparison to patients with plaque psoriasis (PsO), patients with GPP have: a 64% higher score on the Charlson Comorbidity Index; higher hospitalization rates (≤36.3% vs. ≤23.3%); lower overall quality of life, and higher symptom scores for pain, itch, fatigue, anxiety and depression; direct costs associated with treatment 1.3‐ to 4.5‐fold higher; higher rates of disabled work status (20.0% vs. 7.6%); and increased presenteeism (i.e. worse impairment at work), impaired daily activities, and medically related absenteeism. Current medical management and drug treatment utilising non‐GPP‐specific therapies impose a significant patient and direct economic burden. GPP also imposes an indirect economic burden by increasing work productivity impairment and medically related absenteeism. This high level of socioeconomic burden reinforces the need for new therapies with proven efficacy in the treatment of GPP.